The Physician Syndicate

The episode contains a few genuinely interesting operational nuggets - particularly the 'prototype is your currency in medtech' framing and the milestone-versus-momentum capital mindset shift - but these are diluted by extended origin storytelling, networking platitudes, and speculative future-use brainstorming that adds little actionable value for a B2B operator.

“in medtech, your prototype is your currency, right? So how investors look at you, where they, how they judge where you're on the cycle, can you do what you said you were going to do really revolves around that piece of equipment”

“it moves into a more of a momentum um, based denominator. And now it's okay, I've got this million dollars and um, I need to get to my milestone FDA or whatever milestone you've set for the round”

The milestone-to-momentum mindset reframe is a moderately fresh articulation of a well-known medtech fundraising reality, and the simultaneous real-time jugular/carotid Doppler Starling curve concept is technically novel, but the broader startup advice is standard and the future-applications discussion is speculative brainstorming rather than first-principles thinking.

“when you kind of raise that round of capital and you start bringing employees in that it moves into a more of a momentum um, based denominator”

“putting those two together in real time, we can actually create a Doppler Starling curve that you can see evolve”

Joe Eibl is a legitimate practitioner - co-founder and CEO of a real medtech company with FDA, CE, and Health Canada clearance, $19M raised, 33+ peer-reviewed publications, and actual commercial deployments - but the company is still early-stage with only 'low tens' of hospital accounts, and his startup and fundraising experience is limited to a single company at modest scale.

“we've got 33, 34 manuscripts now that are um, published, peer reviewed, describing case reports, uh, across a variety of different, uh, validation studies”

“first time founder, like just getting the mindset”

The episode offers concrete data points - $5M first round, $14M second, FDA/CE/Canada cleared, 33 publications, 4MHz CW ultrasound, Apple watch face form factor, 72-hour use duration, 80%+ device return rates, collaborations with Mayo/UCLA/Health Sciences North - but commercial traction is vague ('low tens' of hospitals) and there are no clinical outcome metrics or revenue figures cited.

“Second round we did 14. So 19 million is the number”

“return rates have been well over 80%”

The host brings genuine clinical credibility - drawing useful parallels to Swan-Ganz catheters, PE thrombolysis monitoring, and vascular surgery - and asks a few sharp technical questions about probe placement difficulty and waveform analysis, but there is no pushback on competitive differentiation, no hard questions about why adoption is limited to 'low tens' of hospitals after years of commercialization, and no challenge to any claim made.

“when you're putting this actual ultrasound probe onto the person's neck, how hard is it actually to place it correctly? Because I know that if you have the wrong angle, especially with the carotid, your waveforms are going to be messed up”

“if you're doing a pe, like thrombolysis case and you, you're just like literally lysing something in the pulmonary and you can just follow along and see what the right jugular is doing”